0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biostax
Its shares trade under the ticker BTAX. It has been listed since 16 July 2001. In the fiscal year to 31 December 2018, it reported revenue of $113,500 and a net loss of $8.2m. At that date it held total assets of $91,600 and shareholders' equity of −$11.3m.
Immune Therapeutics, Inc. engages in the development and marketing of pharmaceutical, biotechnology, and MedTech products. The company is headquartered in Winter Park, Florida. The company went IPO on 2001-07-16. Biostax has partnerships in the fields of autoimmunity and immune restoration, which focuses on delivering solutions for people living with autoimmunity, chronic inflammation, infection, and cancer. Its subsidiary BiostaxRx, is focused on the treatment of inflammaging disease. Its product portfolio includes Londonal, JKB-122 and Low Dose Naltrexone. Lodonal is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). JKB-122 is a therapy developed for the purposes of treating Autoimmune Hepatitis (AIH), Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that shows anti-fibrotic, immune modulating, and/or anti-inflammatory effects.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jul 2001
- Website
- biostaxcorp.com ↗
Leadership
Pay as last reported
- Ms. Kelly WilsonPresident$285,955
- Ms. Noreen GriffinChief Executive Officer, since 2012$111,742
- Mr. Glen FarmerChief Financial Officer$155,334
- Ms. Mary Clay ReynoldsDirector$4,000
- Mr. Roger SuroDirector$3,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biostax Corp has a focused sector in Health Care with a specific industry in Biotechnology.
- The company has a clear product portfolio including Londonal, JKB-122, and Low Dose Naltrexone.
- Biostax Corp has a subsidiary, BiostaxRx, dedicated to treating inflammaging disease.
Weaknesses
- The company's product portfolio includes treatments for specific conditions like HIV/AIDS and Autoimmune Hepatitis, which may limit market reach.
- Biostax Corp's partnerships are limited to autoimmunity and immune restoration, potentially restricting broader applications.
- The company's website is provided but no additional details about its market presence or financial performance are given.
Opportunities
- Biostax Corp could expand its product portfolio to address more prevalent health conditions beyond current focus areas.
- The company may leverage its partnerships in autoimmunity and immune restoration to enter new markets.
- Biostax Corp could explore additional therapeutic areas such as cancer treatment, as mentioned in its focus areas.
Threats
- The company's reliance on specific treatments like HIV/AIDS and Autoimmune Hepatitis may expose it to market volatility.
- Biostax Corp faces competition in the biotechnology sector, though specific competitors are not mentioned.
- The untrusted source description indicates potential inaccuracies, which could affect the reliability of the company's reported information.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.